Showing results (91-100 of 106) with videos related to
Sort By:
Pageof 11
Molecular Genetics and Metabolism|May 21, 2013
Pathogenesis of Morquio A syndrome: an autopsied case reveals systemic storage disorderEriko Yasuda, Kazunari Fushimi, Yasuyuki Suzuki, et al.BMC Cancer|July 28, 2023
A phase Ib/II study of galunisertib in combination with nivolumab in solid tumors and non-small cell lung cancerErnest Nadal, Mansoor Saleh, Santiago Ponce Aix, et al.Biorxiv : the Preprint Server for Biology|July 16, 2025
MYD88 mutations in clonal hematopoiesis promote inflammation and hematopoietic stem cell expansionJennifer Yeung, Sophia Y Philbrook, Emma Uible, et al.Cancer Communications (London, England)|May 22, 2025
A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: durable responses and delayed pseudoprogression in small cell carcinoma of the ovary, hypercalcemic type cohortYoung Kwang Chae, Megan Othus, Sandip Pravin Patel, et al.Journal of Gynecologic Oncology|April 17, 2026
A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: vaginal cancer sub cohort resultsYoung Kwang Chae, Josie Czeskleba, Sandip Pravin Patel, et al.Oncogene|February 24, 2024
Robustness of cancer microbiome signals over a broad range of methodological variationGregory D Sepich-Poore, Daniel McDonald, Evguenia Kopylova, et al.European Journal of Cancer (Oxford, England : 1990)|July 6, 2026
Phase I/Ib study evaluating safety, efficacy, pharmacokinetics and pharmacodynamics of NIZ985 monotherapy and in combination with an anti-PD-1 agent in patients with advanced solid tumors or lymphomaElena Garralda, Patrick Schöffski, Arjun Oberoi, et al.Cancer Immunology, Immunotherapy : CII|April 4, 2023
First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumorsJohanna Bendell, Patricia LoRusso, Michael Overman, et al.Cell|September 30, 2022
Pan-cancer analyses reveal cancer-type-specific fungal ecologies and bacteriome interactionsLian Narunsky-Haziza, Gregory D Sepich-Poore, Ilana Livyatan, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2017
Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring <i>MET</i> Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical ModelsLars D Engstrom, Ruth Aranda, Matthew Lee, et al.Pageof 11